Dihydrotestosterone (DHT) treatment significantly increased PEX10 expression at the mRNA and protein levels in prostate cancer cells, including C4-2 and LNCaP cells, while enzalutamide treatment decreased PEX10 expression, which is consistent with the changes in KLK3 (Fig. 5C–E) and our previous conclusions. Here, PEX10 is linked to Familial prostate cancer.